Tibotec News
 05 November 2011 - INCIVO® (Telaprevir) Demonstrates Efficacy and Increased Cure Rates Among Cirrhotic Patients with Genotype-1 Chronic HCV Compared to Standard of Care
Data to be presented at AASLD 2011 highlights efficacy in typically hard to treat patients
Read more...
23 September 2011 - EDURANT® (rilpivirine) Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in Treatment-Naïve Adults with HIV-1
Third HIV medication submitted by Tibotec
Read more...
20 September 2011 - INCIVO® (Telaprevir) Approved in Europe Offering Higher Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard Therapy
New treatment options increase chance of a cure
Read more...
14 September 2011 - 24 Week INCIVO® (Telaprevir)-Based Regimen Effective for Majority of Previously Untreated Genotype-1 Chronic HCV Patients
ILLUMINATE Phase 3 study published in New England Journal of Medicine
Read more...
22 July 2011 - INCIVO® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) For the Treatment of Genotype-1 Hepatitis C Virus (HCV)
Expanding new treatment class for patients with HCV
Read more...
28 June 2011 - TIBOTEC PHARMACEUTICALS ANNOUNCES AGREEMENT WITH GILEAD SCIENCES
to Develop and Commercialize a New Fixed-Dose Combination of PREZISTA® and COBICISTAT
Read more...
22 June 2011 - Telaprevir-Based Regimens more Effective than Current Standard of Treatment in Curing Genotype 1 HCV Patients
Phase 3 telaprevir studies published in New England Journal of Medicine
Read more...
11 May 2011 - Janssen Identifies Trace Amounts of TBA in 5 Batches of PREZISTA® (darunavir) in the EU and Canada
The Company is Working With Regulatory Authorities
Read more...
18 February 2011 - Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults with Chronic Genotype 1 HCV
Phase 3 program for once-daily TMC435 includes treatment-naïve population and patients who have relapsed after prior interferon-based treatment
Read more...
27 January 2011 - Tibotec Signs Multiple Agreements with Generic Manufacturers to Provide Access to New HIV Treatment
Agreements for Investigational TMC278 Cover Sub-Saharan Africa, India and Least Developed Countries
Read more...
|
